BC Pharmacare approves innohep

Effective February 14, 2017, BC Pharmacare has approved innohep for the additional indication of CAT for up to 6 months. For more information, please click here.

Webinar – Healthcare in the Federal Budget and How It May Affect Patients

Webinar Information: The upcoming federal budget may contain announcements related to the way healthcare is funded in Canada, including changes to the regulation of pharmaceutical prices. Value for taxpayer money should always be the focus for government, but the need for cost-containment needs to be balanced with access to optimal healthcare innovation for patients. Key to this process is the patient voice. Join us for

CCSN Survey on Rituxan (Rituximab)

The purpose of this survey is to provide us with the needed insights and perspectives about the use of Rituxan (Rituximab) for the treatment of patients with Philadelphia chromosome-negative, CD20 antigen positive, B-cell precursor acute lymphoblastic leukemia in adults. Our survey is open until Monday, Feb.27, 2017, as our submission is due to pCODR on Feb. 28. Click here to complete the survey.

BioCanRx, and partners, announce funding to manufacture first made-in-Canada CAR-T cells

Development of promising engineered T cell therapy part of $11 million investment in 16 collaborative research projects in novel therapies to cure cancer OTTAWA, ON – Wednesday, February 15, 2017, 10 a.m. ET – BioCanRx, and its partners, today announced funding for 16 collaborative research projects in novel therapies to cure cancer including research aimed at developing clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities in Canada. CAR-Ts are a powerful new

National Agreement Reached between Pan-Canadian Pharmaceutical Alliance and Bristol-Myers Squibb for Immuno-Oncology Treatment OPDIVO® (nivolumab)

Decisions on public reimbursement now in hands of provincial and territorial jurisdictions MONTREAL, Feb. 10, 2017 /CNW/ – Bristol-Myers Squibb Canada Co. today announced that the company has reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the immuno-oncology treatment OPDIVO®, bringing patients with advanced, difficult-to-treat cancers closer to accessing a new treatment option. This critical agreement for Canadian patients living with metastatic melanomai,